Hormones and Agents Affecting Hormonal Mechanism: Antidiabetic Agents: Oral Hypoglycemic Agents
OTRAJ1 “Trajenta FC tablet” 5 mg/tab
適應症：第二型糖尿病
Usual dose: PO, 5 mg qd.
Dose adjustment:
Geriatric: Refer to adult dosing.
No dose adjustment in renal failure and hepatic insufficiency.
Contraindication:
Hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity) to linagliptin or any component of the formulation
Precaution:
Concomitant use: Insulin secretagogue (eg, sulfonylurea) or insulin may increase risk of hypoglycemia; lower dose of sulfonylurea or insulin may be required.
Gastrointestinal: Acute pancreatitis, including fatalities, has been reported; monitoring recommended and if suspected, immediately discontinue use.
Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.
Adverse effect:
Common:hypoglycemia (monotherapy, 6.6%; combination therapy, 22.9% ) ,Nasopharyngitis (7% )
Serious:Pancreatic cancer, Pancreatitis, Anaphylaxis, Hypersensitivity reaction, Arthralgia (8.1% ), Angioedema, Pancreatic cancer.